7 compounds
Metabolic
Energy, appetite and metabolic-signalling research
AOD-9604
Studied as a C-terminal growth-hormone fragment in adipocyte and lipolysis research models.
Cagrilintide
Studied as an amylin-receptor agonist in satiety and energy-balance research models.
MOTS-c
Studied as a mitochondrial-derived peptide in AMPK signalling and metabolic-homeostasis models.
Retatrutide
Studied as a GIP/GLP-1/glucagon triple-receptor agonist in energy-expenditure and metabolic-signalling models.
Semaglutide
Studied as a long-acting GLP-1 receptor agonist in incretin-pathway and glucose-handling research models.
Survodutide
Studied as a dual GLP-1/glucagon receptor agonist in hepatic and energy-metabolism research models.
Tirzepatide
Studied as a dual GIP/GLP-1 receptor agonist in incretin-signalling and glucose-handling research models.
Metabolic research
All articlesWhat the published literature on these compounds actually examined — the model, the endpoint, and the result.
Metabolic
Amylin, a growth-hormone fragment, and two different evidence levels
Cagrilintide has a published phase 2 trial in humans. AOD-9604 has mouse work and a failed clinical programme. Both sit in the same catalog world.
Metabolic
Incretin receptors: one, two, or three
GLP-1, GIP and glucagon receptors, and what the mono-, dual- and triple-agonist trials actually set out to measure.